2012’s biggest patent expiries

Home/Policies & Legislation | Posted 29/04/2011 post-comment0 Post your comment

Once the patent expiries set for 2011 are gone it is not over for the pharmaceutical industry, as 2012 looks set to be another bumper year for generics, with patents from more of the biggest selling drugs set to expire.

picture 91

Just looking at the top five selling drugs, US sales of more than US$19 billion will be open to competition by the generics industry.

Key patent expiries, according to data from EvaluatePharma, include Plavix (clopidogrel – Bristol-Myers Squibb/sanofi-aventis), Seroquel (quetiapine – AstraZeneca), Singulair (montelukast – Merck), Actos (pioglitazone – Takeda) and Enbrel (etanercept – Amgen). These patent expiries, while being very good news for the generics industry and patients, could deal a major blow to some of the largest pharmaceutical companies.

Brand name Generic name Treatment Company 2010 US sales $
Plavix Clopidogrel Blood thinner BMS/sanofi 6,154,000,000
Seroquel Quetiapine Antipsychotic AstraZeneca 3,747,000,000
Singulair Montelukast Asthma Merck 3,224,000,000
Actos Pioglitazone Diabetes Takeda 3,351,000,000
Enbrel Etanercept Arthritis Amgen 3,304,000,000

BMS: Bristol-Myers Squibb; Sanofi: sanofi-aventis

In 2010, Bristol-Myers Squibb recorded US$6.7 billion in worldwide Plavix sales, or 34% of its total revenues. Sanofi-aventis recorded sales of over Euros 2 billion, or 7% of its 2010 revenues. Worldwide sales of Seroquel amounted to US$5.3 billion in 2010, or nearly 16% of AstraZeneca’s revenues.

Once drugs lose patent protection, lower-price generics rapidly gain market share, often siphoning off as much as 90% of sales. Benefits to patients are substantial, with generics averaging about 30% of the price of the brand-name originals.

Related article

2011’s biggest patent expiries

Source: EvaluatePharma

comment icon Comments (0)
Post your comment
Related content
Generic ‘skinny’ labelling under threat in the US
Label prescription drugs
Home/Policies & Legislation Posted 05/11/2021
FDA publishes final Q&A on biosimilar development and the BPCI Act
Question-Fimea-V15E29
Home/Policies & Legislation Posted 15/10/2021
FDA voices concerns around drug patents and competition
Patent 1 V13E17
Home/Policies & Legislation Posted 08/10/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010